Innate Pharma SA 2017 SR
The report details Innate Pharma's corporate social responsibility performance for the 2017 fiscal year, focusing on its commitment to cancer research and stakeholder transparency. Key highlights include a 22% increase in the workforce to support drug development, with women representing 66% of management positions. The company reported a significant reduction in CO2 emissions from business travel and continued its involvement in the Marseille-Immunopole ecosystem. Environmental efforts focused on managing laboratory waste and energy efficiency, while social initiatives emphasized employee engagement, health and safety, and professional development.
Company: Innate Pharma SA
Sector: Professional & technical services
Country: France
Year: 2017
Type: SR
Pages: 14
Back to company
Innate Pharma SA
Corporate Social Responsibility Report
The report details Innate Pharma's corporate social responsibility performance for the 2017 fiscal year, focusing on its commitment to cancer research and stakeholder transparency. Key highlights include a 22% increase in the workforce to support drug development, with women representing 66% of management positions. The company reported a significant reduction in CO2 emissions from business travel and continued its involvement in the Marseille-Immunopole ecosystem. Environmental efforts focused on managing laboratory waste and energy efficiency, while social initiatives emphasized employee engagement, health and safety, and professional development.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women in Management
Employees